GeoVax Labs Inc
NASDAQ:GOVX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
GeoVax Labs Inc
NASDAQ:GOVX
|
US |
Intrinsic Value
The intrinsic value of GeoVax Labs Inc (GOVX) under the Base Case is 0.8552 USD per share.
Compared with the current market price of 0.1859 USD, the stock appears
Undervalued by 78% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What GeoVax Labs Does
GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is headquartered in Smyrna, Georgia and currently employs 19 full-time employees. Its lead clinical program is GEO-CM04S1, a COVID-19 vaccine, which is in three phase II clinical trials, being evaluated as a primary vaccine for immunocompromised patients, such as those suffering from hematologic cancers and other patient populations for whom the current authorized…
- Headquarters
- United States of America US
- Employees
- 17
- IPO date
- Apr 4, 1994
Revenue & Expenses Breakdown
GeoVax Labs Inc
Earnings Waterfall
GeoVax Labs Inc
The intrinsic value for GeoVax Labs Inc (GOVX) under the Base Case is 0.8552 USD.
Compared with the current market price of 0.1859 USD, the stock appears Undervalued by 78% .